Posts
January 26 2024
Processa Pharmaceuticals, Inc. announced the closing of its Public Offering in the amount of $7,000,000. EG&S acted as counsel to the Placement Agent.
January 25 2024
Psyence Group Inc., a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, announced the completion of its subsidiary Psyence Biomedical Ltd’s merger with Newcourt Acquisition Corp, a special purpose acquisition company. The transaction is valued at approximately $50,000,000. EGS acted as counsel to Psyence Biomed II Corp. and its parent Psyence Group Inc.
January 25 2024
Douglas Ellenoff, a member of the Firm, was invited by SPAC Insider to join their panel of legal SPAC experts, to discuss the SEC’s new SPAC rules.
Click here to register.
January 24 2024
Akoustis Technologies, Inc. announced the closing of its Underwritten Public Offering in the amount of $11,500,000. EG&S acted as counsel to the Underwriter.
January 23 2024
Digital Brands Group, Inc. announced the commencement of its At The Market Offering in the amount of $1,806,937. EG&S acted as counsel to the Sales Agent.
January 22 2024
RedHill Biopharma Ltd. announced the closing of its Registered Direct offering in the amount of $8,000,000. EG&S acted as counsel to the Placement Agent.
January 21 2024
RedHill Biopharma Ltd. announced the closing of its Registered Direct offering in the amount of $8,000,000. EG&S acted as counsel to the Placement Agent.
January 18 2024
TransCode Therapeutics, Inc. announced the closing of its Public Offering in the amount of $7,250,000. EG&S acted as counsel to the Placement Agent.